H. Pieter van den Berg

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial

Annemieke Cats, Edwin P. M. Jansen, Nicole C.T. van Grieken et al. · The Lancet Oncology · 2018 · 562 citations

Surgical Oncology, Chemotherapy Versus Chemoradiotherapy, Gastrointestinal Oncology +8

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

Alfons JM van den Eertwegh, Jurjen Versluis, H. Pieter van den Berg et al. · The Lancet Oncology · 2012 · 356 citations

Tumor Immunology, Urology, Medicine +9

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

Sushil K. Badrising, Vincent van der Noort, Inge M. van Oort et al. · Cancer · 2013 · 135 citations

Health related quality of life in patients with multiple myeloma undergoing a double transplantation

Carin A. Uyl‐de Groot, I. Buijt, I. J. M. Gloudemans et al. · European Journal Of Haematology · 2005 · 49 citations · Full text

Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC)

W.R. Gerritsen, Alfons J. van den Eertwegh, Tanja D. de Gruijl et al. · Journal of Clinical Oncology · 2008 · 44 citations

Urology, Gvax Immunotherapy, Genitourinary Cancer +15